From February 24-27, our team will attend Europe’s leading ADC meeting to connect with clinicians, industry leaders and researchers to discuss how next-generation ADCs can reshape the oncology treatment landscape.
Our Director of Biology, Saskia Schmitt, will share key learnings from our Tubutecan platform and highlight the path of our lead candidate TUB-040 from preclinical development into ongoing clinical trials and its potential therapeutic impact for patients.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information